EA201992447A1 - CONJUGATES OF A QUARTERNIZED INHIBITOR WAY TO RESCUE NICOTINAMIDADENINDININUCLEOTIDE - Google Patents

CONJUGATES OF A QUARTERNIZED INHIBITOR WAY TO RESCUE NICOTINAMIDADENINDININUCLEOTIDE

Info

Publication number
EA201992447A1
EA201992447A1 EA201992447A EA201992447A EA201992447A1 EA 201992447 A1 EA201992447 A1 EA 201992447A1 EA 201992447 A EA201992447 A EA 201992447A EA 201992447 A EA201992447 A EA 201992447A EA 201992447 A1 EA201992447 A1 EA 201992447A1
Authority
EA
Eurasian Patent Office
Prior art keywords
nicotinamidadenindininucleotide
quarternized
rescue
conjugates
unit
Prior art date
Application number
EA201992447A
Other languages
Russian (ru)
Inventor
Кристофер Скотт Нойманн
Кэтлин Оливас
Роберт Лайон
Кунг-Перн Ванг
Original Assignee
Сиэтл Дженетикс, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Сиэтл Дженетикс, Инк. filed Critical Сиэтл Дженетикс, Инк.
Priority claimed from PCT/US2018/030018 external-priority patent/WO2018201087A1/en
Publication of EA201992447A1 publication Critical patent/EA201992447A1/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6859—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from liver or pancreas cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07H—SUGARS; DERIVATIVES THEREOF; NUCLEOSIDES; NUCLEOTIDES; NUCLEIC ACIDS
    • C07H15/00—Compounds containing hydrocarbon or substituted hydrocarbon radicals directly attached to hetero atoms of saccharide radicals
    • C07H15/26—Acyclic or carbocyclic radicals, substituted by hetero rings

Abstract

Раскрыты соединения и композиции, в которых единица NAMPT лекарственного средства конъюгирована с направляющей лигандной единицей посредством кватернизации линкерной единицей, из которых соединение-ингибитор NAMPT или его производное высвобождается в целевом участке действия. Также раскрыты способы лечения заболеваний, характеризующихся измененными клетками-мишенями, такими как измененные клетки при раке или аутоиммунном заболевании, с применением соединений и композиций согласно изобретению.Compounds and compositions are disclosed in which a NAMPT unit of a drug is conjugated to a guiding ligand unit by quaternization with a linker unit, from which a NAMPT inhibitor compound or derivative thereof is released at the target site of action. Methods for treating diseases characterized by altered target cells, such as altered cells in cancer or an autoimmune disease, using the compounds and compositions of the invention are also disclosed.

EA201992447A 2017-10-18 2018-04-27 CONJUGATES OF A QUARTERNIZED INHIBITOR WAY TO RESCUE NICOTINAMIDADENINDININUCLEOTIDE EA201992447A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762573987P 2017-10-18 2017-10-18
PCT/US2018/030018 WO2018201087A1 (en) 2017-04-27 2018-04-27 Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates

Publications (1)

Publication Number Publication Date
EA201992447A1 true EA201992447A1 (en) 2020-03-10

Family

ID=69942838

Family Applications (1)

Application Number Title Priority Date Filing Date
EA201992447A EA201992447A1 (en) 2017-10-18 2018-04-27 CONJUGATES OF A QUARTERNIZED INHIBITOR WAY TO RESCUE NICOTINAMIDADENINDININUCLEOTIDE

Country Status (1)

Country Link
EA (1) EA201992447A1 (en)

Similar Documents

Publication Publication Date Title
CY1124606T1 (en) TARGETED DELIVERY OF MEDICINAL SUBSTANCES CONTAINING TERTITOTAGIC AMINE
EA201990470A1 (en) MEDICINE CONJUGATES WITH SELF-STABILIZING LINKERS HAVING IMPROVED PHYSICAL AND CHEMICAL PROPERTIES
EA201990890A1 (en) TARGET DELIVERY OF REUTILIZATION WAYS OF NIKOTINAMIDADENINDINUCLEOTIDE
CY1124239T1 (en) AMINO-TRIAZOLOPYRIDINE COMPOUNDS AND THEIR USE IN THE TREATMENT OF CANCER
CY1123595T1 (en) BILE ACID DERIVATIVES AS FXR/TGR5 AGENTS
CY1123059T1 (en) A1 RECEPTOR TRANSIENT ION CHANNEL INHIBITION
CY1124243T1 (en) INHIBITING THE A1 TRANSIENT POTENTIAL RECEPTOR ION CHANNEL
BR112018010650A8 (en) prodrugs of a compound jak inhibitor for the treatment of gastrointestinal inflammatory disease
JOP20160092B1 (en) Treatment of beta-thalassemia using actrii ligand traps
MX2019012194A (en) Quaternized nicotinamide adenine dinucleotide salvage pathway inhibitor conjugates.
CL2016000408A1 (en) Pharmaceutical compositions containing macrolide diastereomers, methods for their synthesis and therapeutic uses.
BR112018006016A2 (en) binder-drug intermediate, antibody-drug conjugate compounds, pharmaceutical compositions, methods for treating cancer, method of producing an antibody-drug conjugate and conjugate
CL2019000221A1 (en) Thiazolo-pyridine substituted compounds as malt1 inhibitors.
BR112016029916A2 (en) mnk inhibitors and related methods
EA201691940A1 (en) NEW CONNECTIONS
MX2023002599A (en) Conjugates of quaternized tubulysin compounds.
ES2721001T3 (en) Isoindoline derivative, and compositions and methods to treat a neurodegenerative disease
NZ710729A (en) Amatoxin derivatives
EA201201400A1 (en) COMPOSITIONS AND METHODS OF TREATMENT OF AUTOIMMUNE AND OTHER DISEASES
EA201391485A1 (en) METHODS AND COMPOSITIONS FOR THE TREATMENT OF NEURODEGENERATIVE DISEASES
MX2017005861A (en) Methods to target transcriptional control at super-enhancer regions.
CY1124251T1 (en) CARBOXAMIDE DERIVATIVES
EA202190153A1 (en) AXL / MER INHIBITOR COMPOSITIONS
EA201991196A1 (en) SELF-ASSEMBLED DIBLO-COPOLYMERS CONSISTING OF PEGMEMA AND CARRYING MEDICINE OF POLYMERIC SEGMENTS
EA201790427A1 (en) SUBSTITUTED BICYCLIC COMPOUNDS